GSE137257
Oligosaccharide-dependent anti-inflammatory role of galectin-1 for macrophages in inflammatory bowel disease
Our previous study demonstrated that Galectin-1 plays a protective role for colitis by binding with polylactosamine structures in ß-1,4-galactosyltransferase I-deficient mice, but precise function of galectin-1 remains unknown. In the present study, we investigated about the anti-inflammatory role of galectin-1 for macrophages to ameliorate inflammatory bowel disease in both animal model and human tissue sample. To know the anti-inflammatory effect of galectin-1 in vivo, transfer of BMDMs cultured with galectin-1 into Recombination activating gene (Rag) 2-/- mice and treatment with galectin-1 in dextran sodium sulfate (DSS) colitis model were performed. Furthermore, RNA sequencing was performed to know the character of macrophages treated with galectin-1. In UC patients, tissue expressions of galectin-1 were decreased in inflamed mucosa compared with those in non-inflamed mucosa. Galectin-1 induced IL-10 production in BMDMs, and the production was abrogated by the addition of lactose, which inhibits the interaction of oligosaccharide-galectin binding. DSS colitis was significantly ameliorated in Rag2-/- mice to which galectin-1-treated BMDMs were transferred, than those transferred with vehicle-treated BMDMs. RNA sequence showed that treatment with Galectin-1 increased the expression of CCAAT/enhancer binding protein ß and CD163 but decreased CD80 on BMDMs. Galectin-1 ameliorates murine colitis through the induction of oligosaccharide-dependent anti-inflammatory properties to macrophages. Overall design: To know the anti-inflammatory effect of galectin-1 in vivo, transfer of BMDMs cultured with galectin-1 into Recombination activating gene (Rag) 2-/- mice and treatment with galectin-1 in dextran sodium sulfate (DSS) colitis model were performed. Furthermore, RNA sequencing was performed to know the character of macrophages treated with galectin-1.